Communiqués United Therapeutics Corporation

Actions

UTHR

US91307C1027

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 01/10/2026			Varia. 5j.	Varia. 1 janv.
571,38 ^USD	+5,44%		+21,00%	+17,27%

01/10	Une initiée de United Therapeutics a vendu des actions pour 3 926 177 dollars, selon un récent dépôt auprès de la SEC	MT
01/10	Une dirigeante de United Therapeutics a vendu pour 1 056 425 dollars d’actions, selon un récent dépôt auprès de la Commission américaine des opérations de bourse (SEC)	MT

Communiqués

01/10	United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia	BU
08/09	United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization	BU
02/09	United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis	BU
01/09	United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences	BU
31/08	United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026	AQ
28/08	United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026	BU
24/08	United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension	BU
17/08	United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis	BU
05/08	United Therapeutics: Q2 Earnings Snapshot	AQ
05/08	United Therapeutics Corporation Reports Second Quarter 2026 Financial Results	BU
29/07	United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet	BU
23/07	United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors	BU
22/07	United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026	BU
02/07	United Therapeutics Corporation Acquires Thymmune Therapeutics	BU
29/06	United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion	BU
27/05	United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference	BU
18/05	United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026	BU
18/05	United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial	AQ
17/05	United Therapeutics : Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026	PU
17/05	United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026	BU
16/05	United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial	BU
12/05	United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference	BU
11/05	United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026	BU
06/05	United Therapeutics : First Quarter 2026 Financial Results Presentation	PU
06/05	United Therapeutics : First Quarter 2026 Factsheet	PU